![](https://endpts.com/wp-content/uploads/2023/05/Illumina-shutterstock-tile1.jpg)
Illumina to divest Grail, two years after $8B deal was stymied by antitrust issues
Illumina will divest its cancer diagnostic subsidiary Grail, it announced Sunday, ending a painful years-long saga in which the prized acquisition was held up by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.